


09/891,602

=> d ibib abs hitstr

STN- STRUCTURE SEARCH  
3-12-04

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 2002:31445 CAPLUS  
DOCUMENT NUMBER: 136:86057  
TITLE: Preparation of aza-bridged-bicyclic amino acid derivatives as  $\alpha 4$  integrin antagonists  
INVENTOR(S): Dyatkin, Alexey B.; Maryanoff, Bruce E.; Hoekstra, William J.; He, Wei; Kinney, William A.  
PATENT ASSIGNEE(S): Ortho McNeil Pharmaceutical, Inc., USA  
SOURCE: PCT Int. Appl., 99 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002556	A2	20020110	WO 2001-US20857	20010629
WO 2002002556	A3	20020718		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002091115	A1	20020711	US 2001-891602	20010626
EP 1303492	A2	20030423	EP 2001-952331	20010629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012359	A	20030527	BR 2001-12359	20010629
JP 2004506612	T2	20040304	JP 2002-507808	20010629
NO 2002006252	A	20030226	NO 2002-6252	20021227
PRIORITY APPLN. INFO.:			US 2000-215695P	P 20000630
			US 2001-891602	A 20010626
			WO 2001-US20857	W 20010629
OTHER SOURCE(S):		MARPAT 136:86057		
GI				



AB Aza-bridged-bicyclic amino acid derivs. I [Y = a bond, CO, CO<sub>2</sub>, CONH, SO<sub>2</sub>; R<sub>1</sub> = (un)substituted cycloalkyl, heterocyclyl, aryl, haloalkyl, alkyl, alkenyl, alkynyl, heteroaryl; R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> = H, (un)substituted alkyl, a bond when forming a monocyclic ring; R<sub>6</sub> = one to three

substituents selected from halogen, alkoxy, (un)substituted cycloalkyl, heterocyclyl, aryl, haloalkyl heteroaryl, amino, arylsulfonyl, etc.; A = (un)substituted alkylene; Z1 and Z2 = (un)substituted alkylene or alkenylene] were prepared as  $\alpha 4\beta 1$  and  $\alpha 4\beta 7$  integrin receptor antagonists. Thus, condensation of benzenesulfonyl isocyanate with Et glyoxalate, followed by cycloaddn. with cyclohexadiene, hydrogenation, saponification, coupling with (S)-4-nitrophenylalanine Me ester, reduction of the nitro group, acylation with 2,6-dichlorobenzoyl chloride and ester saponification gave 4-[(2,6-dichlorobenzoyl)amino]-N-[[[(3S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-L-phenylalanine, which showed IC50 = 21nM in Ramos cell adhesion assay.

IT 387336-86-9P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of aza-bridged-bicyclic amino acid derivs. as  $\alpha 4$  integrin antagonists)

RN 387336-86-9 CAPLUS

CN L-Phenylalanine, 4-[(2-carboxybenzoyl)amino]-N-[[[(3S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 387336-52-9P 387336-59-6P 387336-60-9P  
 387336-61-0P 387336-62-1P 387336-63-2P  
 387336-64-3P 387336-65-4P 387336-66-5P  
 387336-67-6P 387336-68-7P 387336-69-8P  
 387336-70-1P 387336-71-2P 387336-72-3P  
 387336-73-4P 387336-74-5P 387336-75-6P  
 387336-76-7P 387336-77-8P 387336-78-9P  
 387336-79-0P 387336-80-3P 387336-81-4P  
 387336-82-5P 387336-83-6P 387336-84-7P  
 387336-85-8P 387336-87-0P 387336-88-1P  
 387336-89-2P 387336-90-5P 387336-91-6P  
 387336-92-7P 387336-93-8P 387336-94-9P  
 387336-95-0P 387336-96-1P 387336-97-2P  
 387336-98-3P 387336-99-4P 387337-00-0P  
 387337-01-1P 387337-02-2P 387337-03-3P  
 387337-04-4P 387337-05-5P 387337-06-6P  
 387337-07-7P 387337-08-8P 387337-11-3P  
 387337-12-4P 387337-13-5P 387337-14-6P  
 387337-15-7P 387337-16-8P 387337-17-9P  
 387337-18-0P 387337-19-1P 387337-20-4P  
 387337-23-7P 387337-24-8P 387337-25-9P  
 387337-26-0P 387337-27-1P 387337-28-2P  
 387337-33-9P 387337-36-2P 387337-37-3P  
 387337-38-4P 387337-40-8P 387337-41-9P  
 387337-44-2P 387337-45-3P 387337-46-4P

09/891,602

**387337-47-5P 387357-67-7P 387357-68-8P**


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aza-bridged-bicyclic amino acid derivs. as  $\alpha 4$  integrin antagonists)

RN 387336-52-9 CAPLUS

CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[[[(3S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 387336-59-6 CAPLUS

CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[[2-[(4-methylphenyl)sulfonyl]-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 387336-60-9 CAPLUS

CN L-Phenylalanine, N-[[2-[(4-methylphenyl)sulfonyl]-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-4-[(2,4,6-trichlorobenzoyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/891,602



RN 387336-61-0 CAPLUS

CN L-Phenylalanine, 4-[(2,6-dimethoxybenzoyl)amino]-N-[[2-[(4-methylphenyl)sulfonyl]-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 387336-62-1 CAPLUS

CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[[2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/891,602



RN 387336-63-2 CAPLUS

CN L-Phenylalanine, 4-[(2-methylbenzoyl)amino]-N-[[2-[(4-methylphenyl)sulfonyl]-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 387336-64-3 CAPLUS

CN L-Phenylalanine, 4-[(2-chlorobenzoyl)amino]-N-[[2-[(4-methylphenyl)sulfonyl]-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/891,602



RN 387336-65-4 CAPLUS

CN L-Phenylalanine, 4-[(2,6-difluorobenzoyl)amino]-N-[[2-[(4-methylphenyl)sulfonyl]-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 387336-66-5 CAPLUS

CN L-Phenylalanine, N-[[2-[(4-methylphenyl)sulfonyl]-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-4-[[2-(trifluoromethyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/891,602



RN 387336-67-6 CAPLUS

CN L-Phenylalanine, N-[[2-[(4-methylphenyl)sulfonyl]-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-4-[[2-(trifluoromethoxy)benzoyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 387336-68-7 CAPLUS

CN L-Phenylalanine, 4-[(2-bromobenzoyl)amino]-N-[[2-[(4-methylphenyl)sulfonyl]-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/891,602



RN 387336-69-8 CAPLUS

CN L-Phenylalanine, 4-[(2,6-difluorobenzoyl)amino]-N-[[2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 387336-70-1 CAPLUS

CN L-Phenylalanine, 4-(benzoylamino)-N-[[2-[(4-methylphenyl)sulfonyl]-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/891,602



RN 387336-71-2 CAPLUS

CN L-Phenylalanine, 4-[[4-(2,5-dimethoxybenzoyl)benzoyl]amino]-N-[[2-[(4-methylphenyl)sulfonyl]-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 387336-72-3 CAPLUS

CN L-Phenylalanine, 4-[[2,6-dichlorophenyl]acetyl]amino]-N-[[2-[(4-methylphenyl)sulfonyl]-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/891,602



RN 387336-73-4 CAPLUS

CN L-Phenylalanine, 4-[[[(2,6-dichlorophenyl)amino]carbonyl]amino]-N-[[2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 387336-74-5 CAPLUS

CN L-Tyrosine, O-[(2,6-dichlorophenyl)methyl]-N-[[2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 387336-75-6 CAPLUS

CN L-Tyrosine, N-[[2-[(4-methylphenyl)sulfonyl]-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

09/891,602


Absolute stereochemistry.



RN 387336-76-7 CAPLUS

CN L-Phenylalanine, N-[[2-[(4-methylphenyl)sulfonyl]-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-4-[[2,4,6-tris(1-methylethyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 387336-77-8 CAPLUS

CN L-Phenylalanine, 4-[[[(2,6-difluorophenyl)amino]carbonyl]amino]-N-[[2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/891,602



RN 387336-78-9 CAPLUS


CN L-Phenylalanine, 3-[(2,6-difluorobenzoyl)amino]-N-[[2-[(4-methylphenyl)sulfonyl]-2-azabicyclo[2.2.2]oct-3-yl]carbonyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 387336-79-0 CAPLUS


CN Phenylalanine, 3-[(2,6-dimethoxybenzoyl)amino]-N-[[2-[(4-methylphenyl)sulfonyl]-2-azabicyclo[2.2.2]oct-3-yl]carbonyl] - (9CI) (CA INDEX NAME)



RN 387336-80-3 CAPLUS


CN Phenylalanine, 3-[(2,6-dichlorobenzoyl)amino]-N-[[2-[(4-methylphenyl)sulfonyl]-2-azabicyclo[2.2.2]oct-3-yl]carbonyl] - (9CI) (CA INDEX NAME)

09/891,602



RN 387336-81-4 CAPLUS


CN Tyrosine, O-[(2,6-dichlorophenyl)methyl]- $\alpha$ -methyl-N-[[2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 387336-82-5 CAPLUS

CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-methyl-N-[[2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 387336-83-6 CAPLUS

CN L-Tyrosine, O-[(2,6-dichlorophenyl)methyl]-N-[[2-(phenylsulfonyl)-2-

09/891,602

azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 387336-84-7 CAPLUS

CN L-Phenylalanine, N-[[2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-4-[(2,4,6-trifluorobenzoyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 387336-85-8 CAPLUS

CN L-Phenylalanine, N-[[2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-4-[(2,3,5,6-tetrafluorobenzoyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/891,602

RN 387336-87-0 CAPLUS

CN L-Phenylalanine, N-[[2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-4-[(4-pyridinylcarbonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 387336-88-1 CAPLUS

CN L-Phenylalanine, N-[[[(3S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-4-[(4-pyridinylcarbonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 387336-89-2 CAPLUS

CN L-Phenylalanine, 4-[[[(2,6-dichlorophenyl)sulfonyl]amino]-N-[[2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/891,602

RN 387336-90-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[(2S)-2-carboxy-2-[[[2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]amino]ethyl]phenyl]amino]carbonyl]-, 1-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 387336-91-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[(2S)-2-carboxy-2-[[[(3S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]amino]ethyl]phenyl]amino]carbonyl]-, 1-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 387336-92-7 CAPLUS

CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[[2-[(4-fluorophenyl)sulfonyl]-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/891,602



RN 387336-93-8 CAPLUS

CN L-Phenylalanine, 4-[(2,6-dimethoxybenzoyl)amino]-N-[[2-[(4-fluorophenyl)sulfonyl]-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 387336-94-9 CAPLUS

CN L-Phenylalanine, N-[[2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-4-[(4-piperidinylcarbonyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/891,602



RN 387336-95-0 CAPLUS

CN L-Phenylalanine, 4-[[[(3,5-dichloro-4-pyridinyl)carbonyl]amino]-N-[[[(3S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 387336-96-1 CAPLUS

CN L-Phenylalanine, 4-[[[(dimethylamino)carbonyl]amino]-N-[[[2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 387336-97-2 CAPLUS

CN L-Tyrosine, O-[(2,6-dichlorophenyl)methyl]-3-fluoro-N-[[[(3S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/891,602



RN 387336-98-3 CAPLUS

CN D-Tyrosine, O-[(2,6-dichlorophenyl)methyl]-3-fluoro-N-[[ (3R)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 387336-99-4 CAPLUS

CN D-Tyrosine, O-[(2,6-dichlorophenyl)methyl]-3-fluoro-N-[[ (3S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 387337-00-0 CAPLUS

CN L-Tyrosine, O-[(2,6-dichlorophenyl)methyl]-3-fluoro-N-[[ (3R)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

09/891,602

NAME)


Absolute stereochemistry.



RN 387337-01-1 CAPLUS

CN L-Phenylalanine, 4-[(2,2-dimethyl-1-oxopropyl)amino]-N-[[[(3S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 387337-02-2 CAPLUS

CN L-Phenylalanine, 4-[[[(2-ethoxy-1-naphthalenyl)carbonyl]amino]-N-[[[(3S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/891,602



RN 387337-03-3 CAPLUS

CN L-Phenylalanine, 4-[(cyclopropylcarbonyl)amino]-N-[[ (3S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 387337-04-4 CAPLUS

CN L-Phenylalanine, N-[[ (3S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-4-[[ (2,2,3,3-tetramethylcyclopropyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/891,602

RN 387337-05-5 CAPLUS

CN L-Phenylalanine, 4-[(2-methyl-1-oxopropyl)amino]-N-[[[(3S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 387337-06-6 CAPLUS

CN L-Phenylalanine, N-[[[(3S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-4-[[[(3S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 387337-07-7 CAPLUS

CN L-Phenylalanine, 4-[[[(1-methylcyclopropyl)carbonyl]amino]-N-[[[(3S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/891,602

RN 387337-08-8 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, 2',6'-dimethoxy- $\alpha$ -[[[(3S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]amino]-, ( $\alpha$ S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 387337-11-3 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, 2',6'-dimethoxy- $\alpha$ -[[[2-[(4-methylphenyl)sulfonyl]-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]amino]-, ( $\alpha$ S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 387337-12-4 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, 2',6'-dimethoxy- $\alpha$ -[[[(3R)-2-[(4-methylphenyl)sulfonyl]-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]amino]-, ( $\alpha$ S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/891,602



RN 387337-13-5 CAPLUS

CN L-Phenylalanine, 4-[[4-(1,1-dimethylethyl)phenyl]ethynyl]-N-[[2-[(4-methylphenyl)sulfonyl]-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 387337-14-6 CAPLUS

CN L-Phenylalanine, N-[[2-[(4-methylphenyl)sulfonyl]-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-4-(phenylethynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/891,602



RN 387337-15-7 CAPLUS

CN L-Phenylalanine, N-[[2-[(4-methylphenyl)sulfonyl]-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 387337-16-8 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid,  $\alpha$ -[[[2-[(4-methylphenyl)sulfonyl]-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]amino]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/891,602



RN 387337-17-9 CAPLUS

CN L-Tyrosine, O-(1,1-dimethylethyl)-N-[[2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 387337-18-0 CAPLUS

CN Benzenebutanoic acid, α-[[[2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 387337-19-1 CAPLUS

CN L-Phenylalanine, 4-(1,1-dimethylethyl)-N-[[2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/891,602



RN 387337-20-4 CAPLUS

CN L-Phenylalanine, 4-[(2,6-difluorobenzoyl)amino]-N-[[[(1R,3S,4S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.1]hept-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 387337-23-7 CAPLUS

CN L-Phenylalanine, 4-[(2,6-difluorobenzoyl)amino]-N-[[[(1R,3R,4S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.1]hept-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 387337-24-8 CAPLUS

CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[[[(1R,3S,4S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.1]hept-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

09/891,602


Absolute stereochemistry.



RN 387337-25-9 CAPLUS

CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[[[(1R,3R,4S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.1]hept-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 387337-26-0 CAPLUS

CN L-Phenylalanine, 4-[(2,6-dimethoxybenzoyl)amino]-N-[[[(1R,3S,4S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.1]hept-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 387337-27-1 CAPLUS

09/891,602

CN L-Phenylalanine, 4-[(2,6-dimethoxybenzoyl)amino]-N-[[[(1R,3R,4S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.1]hept-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 387337-28-2 CAPLUS

CN L-Tyrosine, N-[[[(3S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 387337-33-9 CAPLUS

CN L-Tyrosine, N-[[[2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 387337-36-2 CAPLUS

CN L-Tyrosine, N-[[[2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-, 4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/891,602



RN 387337-37-3 CAPLUS

CN L-Tyrosine, N-[[2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-, bis(1-methylethyl)carbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 387337-38-4 CAPLUS

CN L-Phenylalanine, 4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-N-[[2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 387337-40-8 CAPLUS

CN L-Phenylalanine, 4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-N-[[2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/891,602



RN 387337-41-9 CAPLUS

CN L-Phenylalanine, 4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-[[2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 387337-44-2 CAPLUS

CN L-Tyrosine, N-[[2-(2-thienylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 387337-45-3 CAPLUS

CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[[2-(2-thienylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/891,602



RN 387337-46-4 CAPLUS

CN L-Phenylalanine, 4-[[ (3,5-dichloro-4-pyridinyl) carbonyl] amino] -N-[[2-(2-thienylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl] carbonyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 387337-47-5 CAPLUS

CN L-Phenylalanine, 4-[[ (3,5-dichloro-4-pyridinyl) carbonyl] amino] -N-[[ (3S) -2-(2-thienylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl] carbonyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/891,602



RN 387357-67-7 CAPLUS

CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[[2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-5-en-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 387357-68-8 CAPLUS

CN L-Tyrosine, O-[(2,6-dichlorophenyl)methyl]-N-[[2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-5-en-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 387336-56-3P 387336-57-4P 387336-58-5P  
387337-09-9P 387337-10-2P 387337-31-7P

09/891,602

387337-32-8P 387337-39-5P 387337-42-0P

387337-48-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aza-bridged-bicyclic amino acid derivs. as  $\alpha$ 4 integrin antagonists)

RN 387336-56-3 CAPLUS

CN L-Phenylalanine, 4-nitro-N-[[[(3S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 387336-57-4 CAPLUS

CN L-Phenylalanine, 4-amino-N-[[[(3S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 387336-58-5 CAPLUS

CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[[[(3S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/891,602



RN 387337-09-9 CAPLUS

CN L-Phenylalanine, 4-iodo-N-[[[(3S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 387337-10-2 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, 2',6'-dimethoxy- $\alpha$ -[[[(3S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]amino]-, methyl ester, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 387337-31-7 CAPLUS

CN L-Tyrosine, N-[[[(3S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/891,602



RN 387337-32-8 CAPLUS

CN L-Tyrosine, N-[[[(3S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-, methyl ester, dimethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 387337-39-5 CAPLUS

CN L-Phenylalanine, 4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-N-[[[(3S)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 387337-42-0 CAPLUS

CN L-Phenylalanine, 4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-[[[2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/891,602



RN 387337-48-6 CAPLUS

CN L-Phenylalanine, 4-amino-N-[[2-(phenylsulfonyl)-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 11:56:30 ON 12 MAR 2004)

FILE 'REGISTRY' ENTERED AT 11:56:41 ON 12 MAR 2004

L1 STRUCTURE UPLOADED

L2 1 S L1

L3 89 S L1 FULL

FILE 'CAPLUS' ENTERED AT 11:57:56 ON 12 MAR 2004


L4 1 S L3

=> d l1

L1 HAS NO ANSWERS

L1 STR

09/891,602



Structure attributes must be viewed using STN Express query preparation.

=>